A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors

Acta Oncologica

Volumn 49, Issue 2, 2010, Pages 245-251

  Amarantidis, Kyriakos ^a   Xenidis, Nikolaos ^a   Chelis, Leonidas ^a   Chiotis, Anestis ^b   Tentes, Apostolos ^c   Chatzaki, Ekaterini ^a   Kortsaris, Alexandros ^a   Polychronidis, A ^a   Karakitsos, Petros ^d   Kakolyris, Stylianos ^a  

^a UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^b General Hospital of Xanthi   (Greece)

^c Department of Surgery   (Greece)

^d IASO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DEXAMETHASONE; DOCETAXEL; ONDANSETRON; OXALIPLATIN; PYRIDOXINE; SEROTONIN ANTAGONIST;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DYSESTHESIA; FEMALE; FEVER; FLUSHING; HAND FOOT SYNDROME; HEADACHE; HUMAN; KIDNEY CANCER; MALE; MAXIMUM TOLERATED DOSE; NAIL DISEASE; NEUROPATHY; NEUTROPENIA; PANCREAS CANCER; PLANTAR ERYTHODYSESTHESIA; PLANTAR ERYTHRODYSESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; TAXOIDS;

EID: 76649117118     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841860903253553     Document Type: Article

References (26)

1. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated on human liver and cancer tissue. Eur J Cancer 1998;34:1274-81.
2. Igbal S, Lenz HJ. Capecitabine: The new generation of fluoropyrimides in colorectal cancer. Expert Rev Anticancer Ther 2004;4:947-55.
3. Wagstaff AJ, Ibbotson T, Goa KL. Capecitabine: A review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Drugs 2003;63:217-36.
4. Aprile G, Mazzer M, Moroso S, Puglisi F. Pharmacology and therapeutic efficacy of capecitabine: Focus on breast and colorectal cancer. Anticancer Drugs 2009;20:217-29.
5. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998;16:2977-85.
6. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin. Mechanism of action and antineoplastic activity. Semin Oncol 1998;25 ( Suppl 5 ):4-12.
7. Simpson D, Dunn C, Curran M, Goa KL. Oxaliplatin: A review of its use in combination therapy for advanced meta-static colorectal cancer. Drugs 2003;63:2127-56.
8. Schmoll HJ. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer:Prospects and directions. Semin Oncol 2002;29 ( 5 Suppl 15 ):34-9.
9. Vasile E, Masi G, Fornaro L, Cupini S, Loupakis F, Bursi S, et al. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br J Cancer 2009;100:1720-4.
10. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profi le of oxaliplatin. Semin Oncol 1998;25 ( Suppl 5 ):13-22.
11. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;25:299-303.
12. Pronk L, Vasey PA, Sparreboom A, Reigner B, Planting AS, Gordon RJ, et al. A phase I and pharmacokinetic study of the concentration of capecitabine and docetaxel in patients with advanced solid tumors. Br J Cancer 2000;83:22-9.
13. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine effi cacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-9.
14. Park YH, Ryoo BY, Choi SJ, Kim HT. A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2004;90:1329-33.
15. Han JY, Lee DH, Kim HY, Hong EK, Yoon SM, Chun JH, et al. A phase II study of weekly docetaxel plus capecitabine for patients with advanced non-small cell lung carcinoma. Cancer 2003;98:1918-24.
16. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with docetaxel plus capecitabine combination therapy in anthracycline-pretreated patients with advanced breast cancer:Phase III trial results. J Clin Oncol 2002;20:2812-23.
17. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (capecitabine plus oxaliplatin):Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-91.
18. Scheithauer W, Kornek G, Raderer M, Ulrich-Pur H, Fiebiger W, Gedlicka C, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;21:1307-12.
19. Zeuli M, Constanzo ED, Sdrobolini A, Gasperoni S, Paoloni FP, Capri A, et al. Capecitabine and oxaliplatin in advanced colorectal cancer:A dose-fi nding study. Ann Oncol 2001;12:1737-41.
20. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 2006;12:131-41.
21. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy -induced palmar plantar erythrodysesthesia. Incidence, recognition and management. Am J Clin Dermatol 2000;1:225-34.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
23. Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fl uorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001;19:1096-104.
24. Janinis J, Papadakou M, Xidakis E, Boukis H, Poulis A, Panagos G, et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer:A phase II feasibility study. Am J Clin Oncol 2000;23:128-31.
25. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Costenla M, Boni C, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma:The V-325 Study Group. J Clin Oncol 2007;25:3188-90.
26. Estevez LG, Sanchez Rovira P, Domine M, Leon A, Calvo I, Jaen A, et al. Biweekly docetaxel and capecitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients:Preliminary results of a phase II and pharmacogenomic study. Semin Oncol 2004;31 ( Suppl 5 ):31-6.